Correlation Analysis Between Expression Of Drug Resistance Related Gene And Postoperative Chemotherapeutic Scheme And Prognosis In Non-Small Cell Lung Cancer

ObjectiveTo explore the potentials of Excision Repair Cross Complement-1(ERCC1), Ribonucleotide Reductase M1 (RRM1), ClassⅢ-tubulin (ClassⅢ- tubulin), Multidrug resistence -associated protien (MRP1) and Glutathione-S-transferase P1(GSTP1) in the prediction of prognosis and chemotherapy effects after non-small cell lung cancer (NSCLC) surgeries by studying the association between the expression of ERCC1, RRM1, ClassⅢ-tubulin, MRP1, GSTP1, and the prognosis of platinum chemotherapy. A screening system for sensitive chemotherapy medications after NSCLC surgeries may be established based on the clarification of the physiological mechanism underlying the different sensitivity of NSCLC chemotherapy.MethodsFifty patients with NSCLC undergoing postsurgical platinum chemotherapy were enrolled. The expression of ERCC1, RRM1, ClassⅢ-tubulin, MRP1 and GSTP1 in the resected cancer tissue were detected by immunohistochemistry and compared with the postsurgical survival. The correlation of the expression of the markers and the clinic pathologic factors on the survival time was analyzed.Results1. The positive expression of ERCC1, RRM1, ClassⅢ-tubulin and MRP1,GSTP1 were 46%, 66%, 46%, 60% and 38%.2. Differentiated histologicalgrade, ERCC 1-positive expression,RRM1-positive expression, ClassⅢ-tubulin-positive expression and MRP1-positive expression, GSTP1-positive expression affect the disease-free survival and overall survival.3. Poorly differentiated histologicalgrade, ERCC 1-positive expression were independent prognostic factors. 4. The expression of ERCCI, MRP1, GSTP1 were associated with platinum- based regimens. The positive expression group has shorter disease-free survival time and overall surviva time than negative group.5. The expression of ClassⅢ-tubulin was associated with Paclitaxel-based regimens. The positive expression group has shorter disease-free survival time and overall survival time than negative group.6. The expression of RRMl was associated with gemcitabin-based regimens. The positive expression group has shorter disease-free survival time and overall survival time than negative group.Conclusions1. Poorly differentiated histologicalgrade and ERCC1-positive expression are the independent prognostic fastors.2. The expression of ERCC1, MRP1 and GSTP1 are associated with platinum chemotherapy in NSCLC, and the positive patients have worse outcome. Platinum chemotherapeutic could not be applied in the ERCC1, MRP1, GSTP1-positive patients.3. The expression of ClassⅢ-tubulin is associated with Paclitaxel chemotherapy in NSCLC, and the positive patients have worse outcome. Paclitaxel chemotherapeutic could not be applied in the ClassⅢ-tubulin -positive patients.4. The expression of RRMl is associated with gemcitabine chemotherapy in NSCLC, and the positive patients have worse outcome. Gemcitabine chemotherapeutic could not be applied in the the RRMl -positive patients.5. Therapeutic decision couled be conducted according to the expression of ERCCI, MRP1, GSTP1, ClassⅢ-tubulin and RRMl, which would be a promising method to improve the outcome of NSCLC patients.